Uncategorized

Tessera reveals strongest data yet for in vivo sickle cell therapy

Published

1 month ago

on

BOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex cell engineering or chemotherapy preconditioning …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version